Patients Taking AUSTEDO XR® (deutetrabenazine) - GlobeNewswire
Sep 21, 2025 · The overall patient satisfaction with AUSTEDO XR as a treatment option is further demonstrated by the fact that >96% reported it was easy to take and almost all (96%) expressed …
Real-World Data Show AUSTEDO XR Delivers High Patient Satisfaction …
Teva Pharmaceuticals has announced compelling real-world evidence demonstrating the effectiveness of AUSTEDO XR (deutetrabenazine) extended-release tablets in treating tardive dyskinesia (TD), …
Teva’s New Real-World Evidence Confirms Effectiveness and Patient ...
Apr 19, 2024 · Almost 80% of patients with Huntington's disease (HD) chorea were able to achieve optimal dosing within four weeks with the 4-week Titration Kit in final START study results START …
Austedo XR Shows Symptom Improvement for Patients | Teva
Sep 20, 2025 · Patients taking Austedo XR report symptom improvement and better quality of life in real-world settings.
Teva's AUSTEDO XR Shows 94% Movement Improvement in TD …
Sep 21, 2025 · Teva's AUSTEDO XR shows strong patient satisfaction and symptom improvement in real-world survey, strengthening its position in the TD treatment market. Teva's announcement of …
Teva Presents Real-World Data Showing AUSTEDO XR® Improves …
Sep 20, 2025 · Patients taking AUSTEDO XR reported increased social and emotional well-being as a result of movement reduction, and high overall satisfaction with AUSTEDO XR. The data were …
Reported Saturday, Teva Reports Patients With Tardive Dyskinesia …
Sep 22, 2025 · Of the 209 patients with tardive dyskinesia (TD) that were surveyed, 94% reported movement improvement once treated with AUSTEDO XR® (deutetrabenazine) extended-release …
Teva Pharmaceutical Industries Ltd. - Patients Taking AUSTEDO XR ...
Sep 20, 2025 · Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR® (deutetrabenazine) extended-release …
Study Explores Tardive Dyskinesia Outcomes With Deutetrabenazine Use
Nov 12, 2024 · The survey examined patient-reported ease of use, effectiveness, and satisfaction. In this interim analysis of data from 131 respondents, results revealed that 87% reported satisfaction …
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual …
Apr 16, 2024 · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. …